Fosun International’s Revance Therapeutics, Inc. RVNC Stock Holding History

Fosun International’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-233,841	Closed	-$6.54M	–	225
2021 Q1	$6.54M	Hold	233,841	–	–	0.51%	28
2020 Q4	$6.63K	Hold	233,841	–	–	0.43%	30
2020 Q3	$5.88M	Sell	233,841 -210,000	-47%	-$5.51M	0.52%	30
2020 Q2	$10.8M	Sell	443,841 -25,491	-5%	-$503K	1.04%	19
2020 Q1	$6.95M	Sell	469,332 -3,200	-0.7%	-$66.2K	0.68%	25
2019 Q4	$7.67M	Hold	472,532	–	–	0.64%	23
2019 Q3	$6.14M	Hold	472,532	–	–	0.68%	22
2019 Q2	$6.13M	Hold	472,532	–	–	0.4%	38
2019 Q1	$7.45M	Hold	472,532	–	–	0.47%	33
2018 Q4	$9.51M	Hold	472,532	–	–	0.57%	29
2018 Q3	$11.7M	Hold	472,532	–	–	0.56%	26
2018 Q2	$13M	Buy	472,532 +153,219	+48%	+$4.61M	0.66%	33
2018 Q1	$9.84M	Buy	+319,313	New	+$10.3M	0.62%	34

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fosun International's RVNC Position: Q2 2021 in Review

Fosun International sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2021, closing a stake of 233,841 shares — an estimated $6.54M sold.

Fosun International first reported a position in RVNC in Q1 2018 and held it in 13 quarters. The position peaked at $13M in Q2 2018. 161 funds tracked by Wall St. Rank hold RVNC as of Q2 2021.

Fosun International reported no remaining Revance Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Fosun International sold 233,841 Revance Therapeutics, Inc. shares in Q2 2021, an estimated $6.54M.
Fosun International first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 13 quarters.
Fosun International's Revance Therapeutics, Inc. position peaked at $13M in Q2 2018.
161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2021.

Based on Fosun International's 13F filing for Q2 2021, filed 12 Aug 2021.